Taleo

Taleo Therapeutics is a biotechnology company focused on developing next-generation immune tolerance therapies for autoimmune and inflammatory diseases. The company's proprietary platform utilizes synthetic glycosylation to target specific antigens to the liver, leveraging the organ's natural ability to induce immune tolerance. By presenting antigens in a tolerogenic context, Taleo aims to treat diseases such as Type 1 Diabetes and Multiple Sclerosis without the need for broad immunosuppression. The company was founded by pioneers in immuno-engineering and is backed by leading life science investors including ARCH Venture Partners.